Up a level |
Buehler, A., Berger, S., Bengsch, F., Martin, G., Han, H., Vierkotten, S., Pielen, A., Boehringer, D., Schlunck, G., Fauser, S., Agostini, H. T., Reinheckel, T. and Stahl, A. (2013). Cathepsin proteases promote angiogenic sprouting and laser-induced choroidal neovascularisation in mice. Exp. Eye Res., 115. S. 73 - 79. LONDON: ACADEMIC PRESS LTD- ELSEVIER SCIENCE LTD. ISSN 1096-0007
Buehler, A., Wendtner, C-M, Kipps, T. J., Rassenti, L., Fraser, G. A. M., Michallet, A-S, Hillmen, P., Duerig, J., Gregory, S. A., Kalaycio, M., Aurran-Schleinitz, T., Trentin, L., Gribben, J. G., Chanan-Khan, A., Purse, B., Zhang, J., De Bedout, S., Mei, J., Hallek, M. and Stilgenbauer, S. (2016). Lenalidomide treatment and prognostic markers in relapsed or refractory chronic lymphocytic leukemia: data from the prospective, multicenter phase-II CLL-009 trial. Blood Cancer J., 6. LONDON: NATURE PUBLISHING GROUP. ISSN 2044-5385
Edelmann, J., Haferlach, C., Saub, J., Teleanu, V, Florence, C., Leblonde, V, Delmer, A., Buehler, A., Gribben, J. G., Hallek, M., Doehner, H. and Stilgenbauer, S. (2014). Genomic characterization of primary ultra high-risk and refractory chronic lymphocytic leukemia: Results from the CLL2O trial. Oncol. Res. Treat., 37. S. 220 - 221. BASEL: KARGER. ISSN 2296-5262
Elter, T., James, R., Busch, R., Winkler, D., Ritgen, M., Boettcher, S., Kahl, C., Gassmann, W., Stauch, M., Hasan, I., Staib, P., Fischer, K., Fink, A-M, Bahlo, J., Buehler, A., Doehner, H., Wendtner, C-M, Stilgenbauer, S., Engert, A. and Hallek, M. (2012). Fludarabine and cyclophosphamide in combination with alemtuzumab in patients with primary high-risk, relapsed or refractory chronic lymphocytic leukemia. Leukemia, 26 (12). S. 2549 - 2554. LONDON: NATURE PUBLISHING GROUP. ISSN 0887-6924
Hallek, M., Fischer, K., Fingerle-Rowson, G., Fink, A. M., Busch, R., Mayer, J., Hensel, M., Hopfinger, G., Hess, G., von Gruenhagen, U., Bergmann, M., Catalano, J., Zinzani, P. L., Caligaris-Cappio, F., Seymour, J. F., Berrebi, A., Jaeger, U., Cazin, B., Trneny, M., Westermann, A., Wendtner, C. M., Eichhorst, B. F., Staib, P., Buehler, A., Winkler, D., Zenz, T., Boettcher, S., Ritgen, M., Mendila, M., Kneba, M., Doehner, H. and Stilgenbauer, S. (2010). Addition of rituximab to fludarabine and cyclophosphamide in patients with chronic lymphocytic leukaemia: a randomised, open-label, phase 3 trial. Lancet, 376 (9747). S. 1164 - 1175. NEW YORK: ELSEVIER SCIENCE INC. ISSN 0140-6736
Hoechstetter, M. A., Busch, R., Eichhorst, B., Buehler, A., Winkler, D., Bahlo, J., Eckart, M. J., Vehling-Kaiser, U., Schimke, H., Jaeger, U., Hurtz, H. J., Hopfinger, G., Hartmann, F., Fuss, H., Abenhardt, W., Blau, I., Freier, W., Mueller, L., Goebeler, M., Wendtner, C. M., Fischer, K., Bentz, M., Emmerich, B., Doehner, H., Hallek, M. and Stilgenbauer, S. (2017). A new prognostic model based on clinical, biological and genetic parameters improves prognostication in early stage CLL patients: results of the prospective CLL1 trial of the German CLL study group. Oncol. Res. Treat., 40. S. 25 - 27. BASEL: KARGER. ISSN 2296-5262
Hoechstetter, M. A., Busch, R., Eichhorst, B., Buehler, A., Winkler, D., Eckart, M. J., Vehling-Kaiser, U., Schimke, H., Jaeger, U., Hurtz, H. J., Hopfinger, G., Hartmann, F., Fuss, H., Abenhardt, W., Blau, I., Freier, W., Mueller, L., Goebeler, M., Wendtner, C. M., Bahlo, J., Fischer, K., Bentz, M., Emmerich, B., Doehner, H., Hallek, M. and Stilgenbauer, S. (2017). Early, risk-adapted treatment with fludarabine in Binet stage A chronic lymphocytic leukemia patients: results of the CLL1 trial of the German CLL study group. Leukemia, 31 (12). S. 2833 - 2838. LONDON: NATURE PUBLISHING GROUP. ISSN 1476-5551